CNBC’s Jim Cramer warned the recent gains in Alphabet could be short lived when the company reports earnings in coming weeks. The “Mad Money” host broke down the movements in other stocks that he said aren’t “momentum” based. Later in the show he sat down with GlaxonSmithKline CEO Emma Walmsley and CVS Health CEO Larry Merlo as he attends the J. P. Morgan Healthcare Conference in San Francisco.
Does Alphabet deserve to cross the $1 trillion mark?
Carsten Koall | Getty Images
is close to joining one of the most elusive clubs on Wall Street, but CNBC’s said Monday that he is skeptical of the progress.
Shares in Alphabet, the tech giant that owns Google, rose almost $10 to an all-time closing high of $1,440.03, pulling within 1% of reaching $1 trillion of market capitalization.
“Now, I don’t like this move. It’s based on nothing fundamental, just the momentum that we see in so many tech names,” the “Mad Money” host said.
Meaningful gains in Tesla, Lululemon, Beyond Meat
Tesla CEO Elon Musk and Shanghai’s Mayor Ying Yong attend the Tesla Shanghai Gigafactory groundbreaking ceremony in Shanghai, China January 7, 2019.
Aly Song | Reuters
Cramer has been hammering home the difference between meaningless and meaningful gains on the stock market and on Monday laid out a basket of companies that are rising for good reason.
“We don’t want to be in a situation where stocks keep roaring on the same old, same old information, so it’s a relief to see a bunch of winners rallying on genuine good news,” the host said.
GlaxoSmithKline aims for six drug approvals in 2020
A GSK lab in London.
Oli Scarff | Getty Images
has made innovation its top priority as the drugmaker seeks to land federal approval of six drugs within the next 12 months, CEO Emma Walmsley told CNBC.
Performance and trust round out the balance of GSK’s main priorities in 2020 as the British company labors to make advancements in treatments for a number of diseases, Walmsley said in a “Mad Money” interview from J.P. Morgan’s annual health-care conference in San Francisco.
“We’ve had a lot of positive data for patients, whether that be on the Tesaro acquisition … or our new drug in multiple myeloma,” she said in a sit-down with Cramer. “We have a lot of data coming through for HIV patients, in terms of these pioneering two-drug regimens, and we hope that this data among others is going to give us at least six approvals of new medicines or new indications” this year.
Six hundred and counting
CVS’ new concept stores, called HealthHUBs, offer more health services than its typical drugstores.
Source: CVS Health
CEO Larry Merlo told CNBC that the health retailer is on track to meet its goal of rehabbing more than one thousand of its stores and said the chain is seeing positive early results.
CVS launched three of its HealthHUB concept stores in the Houston, Texas region near the end of 2018 and expanded the program to 50 locations in four markets by the end of 2019, he said. Hundreds more are scheduled to be overhauled by the end of 2020.
“We’re really excited about what we’re seeing from the consumers. The acceptance, the interest that is growing with our clients,” Merlo said in a sit-down interview with Cramer. “We’ve made a commitment to have about 600 hubs by the end of this year. That’s 12 [updated stores] a week with a trajectory of 1,500 hubs by the end of 2021.”
Cramer’s lightning round
In Cramer’s lighting round, the “Mad Money” host delivered his thoughts about callers’ favorite stock picks of the day in rapid speed.
: “This stock is not down as well as I thought because I think that the acquisition was a brilliant acquisition. Others don’t. I think they’re wrong. [CEO] Bryan Jordan understands.”
.: “I’m not going to disagree with you. I think it is a value play, as long as you accept that. I do like Valero more than HFC, but I definitely understand why you want to buy a stock that’s down and out.”
Disclosure: Cramer’s charitable trust owns shares of Alphabet and CVS Health.